Company Overview

Resverlogix Corp. (OTCQB: RVXCF; TSX: RVX) is a Canadian biotechnology company focused on the development of epigenetic therapies targeting chronic diseases with significant unmet medical needs. The company operates primarily in the biopharmaceutical and precision medicine sectors, with research centered on bromodomain and extraterminal domain (BET) protein inhibition. Its lead drug candidate, apabetalone (RVX-208), has been studied for cardiovascular disease, chronic kidney disease, diabetes-related complications, and other conditions associated with inflammation and vascular dysfunction.

The company’s primary revenue and enterprise value drivers have historically been tied to the clinical development and licensing potential of apabetalone and related BET-inhibitor technologies. Resverlogix has positioned itself within the emerging field of epigenetics by focusing on selective BET inhibition intended to regulate gene expression without altering DNA sequences directly. Founded in 2001 and headquartered in Calgary, Alberta, the company evolved from an early-stage cardiovascular therapeutics developer into a specialized epigenetics-focused biotechnology company pursuing partnerships, intellectual property monetization, and clinical validation of its platform technologies.

Business Operations

Resverlogix’s operations are centered on biotechnology research and drug development rather than commercial pharmaceutical sales. The company’s principal operating activities include clinical trials, intellectual property development, regulatory engagement, and partnership discussions related to its BET inhibitor platform. Its core asset, apabetalone, has undergone multiple clinical studies evaluating effects on major adverse cardiovascular events, chronic kidney disease biomarkers, and inflammatory pathways. The company also maintains a portfolio of patents covering BET protein inhibition and epigenetic therapeutic applications.

Operations are primarily based in Canada, though the company has conducted clinical programs involving sites and collaborators in the United States, Europe, and other international markets. Resverlogix historically collaborated with external research institutions, contract research organizations, and pharmaceutical partners to advance clinical development. The company has also referenced relationships with academic and medical research centers supporting biomarker analysis and mechanistic studies. Public filings indicate that the company’s business model relies heavily on financing activities, strategic collaborations, and potential licensing arrangements rather than recurring operating revenue.

Strategic Position & Investments

Resverlogix’s strategic direction has focused on advancing epigenetic therapeutics through selective BET inhibition while seeking commercial partnerships and financing support for late-stage development activities. The company has emphasized the potential role of apabetalone in addressing inflammatory and cardiovascular diseases linked to diabetes and renal impairment. Clinical findings from studies such as BETonMACE have been central to the company’s long-term strategy, although public disclosures indicate mixed outcomes regarding primary clinical endpoints and subsequent commercialization pathways.

The company has invested substantially in intellectual property protection and clinical research associated with BET-targeting compounds. Resverlogix has also explored opportunities in broader cardiometabolic and inflammatory disease applications, reflecting growing industry interest in epigenetic modulation technologies. Publicly available filings and investor materials indicate continued focus on strategic financing, regulatory engagement, and partnership development to support future clinical and commercial activities. Data regarding major acquisitions or large-scale subsidiary holdings remains limited in publicly available records.

Geographic Footprint

Resverlogix is headquartered in Calgary, Alberta, Canada, and its operational footprint has historically extended into multiple international clinical research markets. The company’s clinical studies and scientific collaborations have involved institutions and trial sites across North America and portions of Europe, particularly in regions with established cardiovascular and metabolic disease research infrastructure.

Although Resverlogix does not maintain the global commercial presence of a large pharmaceutical company, its intellectual property portfolio and clinical programs have been developed with international regulatory and partnership potential in mind. Public disclosures indicate engagement with healthcare and research stakeholders in the United States, which remains a strategically important market for biotechnology financing, regulatory approvals, and potential commercialization opportunities.

Leadership & Governance

Resverlogix was founded under the leadership of executives and scientific personnel focused on cardiovascular therapeutics and epigenetic medicine development. The company’s governance structure follows the standards applicable to publicly traded Canadian biotechnology issuers, with oversight provided through its board of directors and executive leadership team. Management communications have consistently emphasized long-term value creation through scientific validation, intellectual property development, and strategic partnerships in the epigenetics field.

Key executives and leadership figures identified in public filings and company disclosures include:

• Donald J. McCaffrey – President and Chief Executive Officer
• Mitchell F. Steiner, M.D. – Executive Vice President, Research and Development
• Byron Purves – Chief Financial Officer
• Henry J. Kuta – Chairman of the Board (historically referenced in company governance materials)

Leadership communications in investor presentations and public filings have emphasized advancing precision epigenetic therapies for chronic disease management, while pursuing regulatory and strategic pathways to maximize the commercial potential of the company’s BET inhibition platform.